Paradoxical attenuation of autoimmune hepatitis by oral isoniazid in wild-type and n-acetyltransferase-deficient mice

Drug Metabolism and Disposition

Volumn 42, Issue 6, 2014, Pages 963-973

  Metushi, Imir G ^a   Cai, Ping ^b   Vega, Libia ^c   Grant, Denis M ^a,b   Uetrecht, Jack ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ANTIGEN; CD11B ANTIGEN; CD4 ANTIGEN; CD45R ANTIGEN; CD8 ANTIGEN; F4/80 ANTIGEN; FREUND ADJUVANT; GLUTAMIC ACID; IDITOL DEHYDROGENASE; ISONIAZID; ISONICOTINIC ACID; KI 67 ANTIGEN; LEUKOCYTE ANTIGEN; NARYLAMINE ACYLTRANSFERASE; UNCLASSIFIED DRUG; ARYLAMINE ACETYLTRANSFERASE; NAT2 ENZYME, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; DISEASE MODEL; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; IMMUNIZATION; IMMUNOCYTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KNOCKOUT MOUSE; LIVER INJURY; LIVER MITOCHONDRION; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEATOSIS; TREATMENT DURATION; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; ENZYMOLOGY; FATTY LIVER; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; FATTY LIVER; FEMALE; HEPATITIS, AUTOIMMUNE; ISONIAZID; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84901008930     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.056622     Document Type: Article

References (39)

1. Benoit M, Desnues B, and Mege JL (2008) Macrophage polarization in bacterial infections. J Immunol 181:3733-3739.
2. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, and Epler GR (1975) Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69:289-302.
3. Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, and Dhali GK (2006) Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 45:117-126.
4. De Valle MB, Av Klinteberg V, Alem N, Olsson R, and Björnsson E (2006) Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 24:1187-1195.
5. Eaddy J, Wu H, Adkins K, Watkins P, and Harril AH (2012) Population-based toxicity assessment implicates mitochondrial dysfunction as an early event in isoniazid-induced liver injury. The Toxicologist (Supplement to Toxicological Sciences) 126:22. Abst 113.
6. Fairweather D and Cihakova D (2009) Alternatively activated macrophages in infection and autoimmunity. J Autoimmun 33:222-230.
7. Foureau DM, Walling TL, Kleiner DE, Ahrens WA, Jacobs WC, McKillop IH, Barnhart HX, Serrano J, and Bankovsky H (2012) Profiles of leukocytes infiltrating livers of subjects with drug-induced liver injury (DILI). Hepatology 56:596A (Abst 827).
8. Fukino K, Sasaki Y, Hirai S, Nakamura T, Hashimoto M, Yamagishi F, and Ueno K (2008) Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 33:187-195.
9. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, and Lee SD (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883-889.
10. Laskin DL (2009) Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem Res Toxicol 22:1376-1385.
11. Lohse AW, Manns M, Dienes HP, Meyer zum Büschenfelde KH, and Cohen IR (1990) Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 11:24-30.
12. Maddrey WC and Boitnott JK (1973) Isoniazid hepatitis. Ann Intern Med 79:1-12.
13. Maria VA and Victorino RM (1997) Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 41:534-540.
14. McGill MR, Williams CD, Xie Y, Ramachandran A, and Jaeschke H (2012) Acetaminopheninduced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. Toxicol Appl Pharmacol 264:387-394.
15. Metushi IG, Cai P, Zhu X, Nakagawa T, and Uetrecht JP (2011) A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 89:911-914.
16. Metushi IG, Nakagawa T, and Uetrecht J (2012) Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem Res Toxicol 25:2567-2576.
17. Metushi IG and Sanders C, The Acute Liver Study G, Lee WM, and Uetrecht J (2014) Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology P59:1084-1093.
18. Metushi IG and Uetrecht J (2013) Isoniazid-induced liver injury and immune response in mice. J Immunotoxicol. (DOI: 10.3109/1547691X.2013.860644)
19. Metushi IG and Uetrecht J (2014) Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin. Mol Cell Biochem 387;9-17.
20. Mitchell JR, Long MW, Thorgeirsson UP, and Jollow DJ (1975) Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 68: 181-190.
21. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, and Nelson SD (1976) Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84:181-192.
22. Monshouwer M, McLellan RA, Delaporte E, Witkamp RF, van Miert AS, and Renton KW (1996) Differential effect of pentoxifylline on lipopolysaccharide- induced downregulation of cytochrome P450. Biochem Pharmacol 52:1195-1200.
23. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, and Corcoran GB, 3rd (1976) Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 193: 901-903.
24. Njoku DB, Talor MV, Fairweather D, Frisancho-Kiss S, Odumade OA, and Rose NR (2005) A novel model of drug hapten-induced hepatitis with increased mast cells in the BALB/c mouse. Exp Mol Pathol 78:87-100.
25. O?Brien PJ, Slaughter MR, and Polley SR, and Kramer K (2002) Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab Anim 36: 313-321.
26. Pessayre D, Bentata M, Degott C, Nouel O, Miguet JP, Rueff B, and Benhamou JP (1977) Isoniazid-rifampin fulminant hepatitis: a possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology 72:284-289.
27. Pilheu JA, De Salvo MC, and Barcat JA (1979) [Effect of isoniazid and rifampicin regimens on the liver of tuberculosis patients]. Medicina (B Aires) 39:298-304.
28. Pilheu JA, de Salvo MC, Koch O, and Barcat JA (1981) [Light and electron microscopy studies of the liver in tuberculosis patients receiving rifampin and isoniazid]. Medicina (B Aires) 41:439-445.
29. Projean D, Dautrey S, Vu HK, Groblewski T, Brazier JL, and Ducharme J (2005) Selective downregulation of hepatic cytochrome P450 expression and activity in a rat model of inflammatory pain. Pharm Res 22:62-70.
30. Pulendran B, Tang H, and Manicassamy S (2010) Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol 11:647-655.
31. Salazar-P?ramo M, Rubin RL, and Garc?a-De La Torre I (1992) Systemic lupus erythematosus induced by isoniazid. Ann Rheum Dis 51:1085-1087.
32. Sarich TC, Youssefi M, Zhou T, Adams SP, Wall RA, and Wright JM (1996) Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch Toxicol 70:835-840.
33. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, and Hillon P (2002) Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36:451-455.
34. Sodhi CP, Rana SV, Mehta SK, Vaiphei K, Attari S, and Mehta S (1997) Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats. Drug Chem Toxicol 20:255-269.
35. Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, and Grant DM (2003) Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 doubleknockout mice. Mol Pharmacol 64:170-179.
36. Thiele GM, Duryee MJ, Willis MS, Tuma DJ, Radio SJ, Hunter CD, Schaffert CS, and Klassen LW (2010) Autoimmune hepatitis induced by syngeneic liver cytosolic proteins biotransformed by alcohol metabolites. Alcohol Clin Exp Res 34:2126-2136.
37. Timbrell JA, Mitchell JR, Snodgrass WR, and Nelson SD (1980) Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 213:364-369.
38. Warrington RJ, McPhilips-Feener S, and Rutherford WJ (1982) The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis. Clin Allergy 12:217-222.
39. Warrington RJ, Tse KS, Gorski BA, Schwenk R, and Sehon AH (1978) Evaluation of isoniazidassociated hepatitis by immunological tests. Clin Exp Immunol 32:97-104.